Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study
Ramandip Grewal, Sarah A. Buchan, Lena Nguyen, Sharifa Nasreen, Peter C. Austin, Kevin A. Brown, Jonathan B. Gubbay, Nelson Lee, Kevin L. Schwartz, Mina Tadrous, Kumanan Wilson, Sarah E Wilson, Jeffrey C. Kwong
Abstract
We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.
Topics & Concepts
Bivalent (engine)Booster (rocketry)Coronavirus disease 2019 (COVID-19)MedicineBooster doseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunizationImmunologyChemistryDiseaseAntibodyPhysicsInternal medicineInfectious disease (medical specialty)MetalOrganic chemistryAstronomySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyInfluenza Virus Research Studies